Alimera Sciences, Inc. (NASDAQ:ALIM) insider Richard S. Eiswirth, Jr. sold 14,494 shares of the stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $1.23, for a total value of $17,827.62. Following the completion of the transaction, the insider now directly owns 98,619 shares in the company, valued at approximately $121,301.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Alimera Sciences, Inc. (NASDAQ ALIM) remained flat at $$1.24 on Friday. The stock had a trading volume of 283,400 shares, compared to its average volume of 168,400. The company has a debt-to-equity ratio of -0.71, a current ratio of 4.84 and a quick ratio of 4.65. Alimera Sciences, Inc. has a 52 week low of $1.11 and a 52 week high of $1.72. The firm has a market cap of $81.60, a PE ratio of -4.00 and a beta of 2.15.
Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. equities analysts forecast that Alimera Sciences, Inc. will post -0.27 earnings per share for the current fiscal year.
An institutional investor recently raised its position in Alimera Sciences stock. Stonepine Capital Management LLC increased its holdings in shares of Alimera Sciences, Inc. (NASDAQ:ALIM) by 158.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 477,226 shares of the biopharmaceutical company’s stock after purchasing an additional 292,399 shares during the quarter. Alimera Sciences makes up 0.4% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned approximately 0.69% of Alimera Sciences worth $644,000 as of its most recent SEC filing. Institutional investors own 41.78% of the company’s stock.
A number of research analysts have weighed in on ALIM shares. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Alimera Sciences in a report on Friday, October 27th. Cowen reissued a “buy” rating on shares of Alimera Sciences in a report on Thursday, November 2nd. Zacks Investment Research downgraded Alimera Sciences from a “hold” rating to a “sell” rating in a report on Monday, November 27th. Finally, ValuEngine raised Alimera Sciences from a “strong sell” rating to a “sell” rating in a report on Friday, October 20th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $3.38.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.